Across TCGA pan-cancer cohorts, SLC25A36 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated SLC25A36 data layer compared with 22 for mass-spec protein and 3 for mass-spec protein.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SLC25A36 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SLC25A36 expression acts as an unfavorable survival marker.
HNSC are the cancer types where SLC25A36 Mutation most reproducibly stratifies survival.